FAM225A and hepatocellular carcinoma: Additionally, dysregulation of FAM225A and miR-130a-5p remarkably affected hepatoma cell sensitivity to sorafenib via targeting Cyclin G1 (CCNG1), which might provide us with more potential therapeutic strategies for chemosensitization of HCC cells to sorafenib.